Adimab is a leading antibody discovery company with over 450 discovery campaigns and 55 clinical programs created with 100+ partners. Their yeast-based platform is effective for discovering and optimizing fully human monoclonal and bispecific antibodies. They work with big pharma, biotech companies, and academic institutions to create high-quality protein-based therapeutics, including IgGs, multispecifics, and CARs.